Aligos Therapeutics, Inc. (ALGS) Ownership
ALGS ownership summary
as of October 18, 2026- Institutions
- 42.2% of shares outstanding
- Insiders
- 10.64% of shares outstanding
- Shares outstanding
- 5.4M
- Float
- 3.7M shares available to trade
- Short interest
- 13.36% 709K shares short
- Days to cover
- 14.01 short interest up 1.6% vs prior month
- Institutions 42.16%
- Insiders 10.64%
- Other investors 47.19%
ALGS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 7.11% | 444K | $2.2M | — | June 30, 2026 |
| 2 | Alyeska Investment Group, L.P. | 6.60% | 412K | $2.0M | — | June 30, 2026 |
| 3 | Sio Capital Management, LLC | 5.24% | 327K | $1.6M | — | June 30, 2026 |
| 4 | Marshall Wace Asset Management Ltd | 3.95% | 247K | $1.2M | −20,556 (−7.7%) | June 30, 2026 |
| 5 | Woodline Partners LP | 2.84% | 177K | $861,979 | — | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 2.81% | 176K | $853,139 | −2,719 (−1.5%) | June 30, 2026 |
| 7 | Baker Bros Advisors LP | 1.33% | 83K | $403,647 | — | June 30, 2026 |
| 8 | Hillhouse Capital Advisors, Ltd. | 1.22% | 76K | $370,560 | — | June 30, 2026 |
| 9 | D. E. Shaw & Co LP | 1.06% | 66K | $323,010 | +55,485 (+505.4%) | June 30, 2026 |
| 10 | UBS Group AG | 0.96% | 60K | $291,532 | +22,925 (+61.9%) | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 0.76% | 47K | $229,261 | −2,802 (−5.6%) | June 30, 2026 |
| 12 | Jane Street Group LLC | 0.52% | 32K | $157,474 | +32,402 (0.0%) | June 30, 2026 |
| 13 | BlackRock Inc | 0.49% | 30K | $147,219 | +17,252 (+132.3%) | June 30, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 0.46% | 29K | $139,054 | +175 (+0.6%) | June 30, 2026 |
| 15 | Dimensional Fund Advisors, Inc. | 0.34% | 21K | $102,274 | +21,044 (0.0%) | June 30, 2026 |
| 16 | Verition Fund Managegment, LLC | 0.30% | 19K | $91,791 | — | June 30, 2026 |
| 17 | Trexquant Investment LP | 0.20% | 12K | $59,968 | +12,339 (0.0%) | June 30, 2026 |
| 18 | Renaissance Technologies Corp | 0.17% | 11K | $52,488 | −89,650 (−89.2%) | June 30, 2026 |
| 19 | Rockefeller Capital Management L.P. | 0.16% | 10K | $48,600 | — | June 30, 2026 |
| 20 | Federation des caisses Desjardins du Quebec | 0.07% | 4,650 | $22,599 | +3,700 (+389.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 165K shares and 4 cut 116K.
ALGS top mutual fund and ETF holders
17 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.06% | 129K | $625,822 | — | August 31, 2026 |
| 2 | Fidelity Extended Market Index | 0.43% | 27K | $130,258 | +4,683 (+21.2%) | August 31, 2026 |
| 3 | iShares Micro-Cap ETF | 0.25% | 16K | $76,166 | −108 (−0.7%) | September 30, 2026 |
| 4 | DFA US Micro Cap I | 0.13% | 8,329 | $40,479 | — | August 31, 2026 |
| 5 | Fidelity Total Market Index | 0.12% | 7,553 | $36,708 | — | August 31, 2026 |
| 6 | Fidelity Series Total Market Index | 0.10% | 6,141 | $29,845 | — | August 31, 2026 |
| 7 | DFA US Small Cap I | 0.06% | 3,573 | $17,365 | — | August 31, 2026 |
| 8 | Dimensional US Small Cap ETF | 0.04% | 2,810 | $13,657 | — | September 30, 2026 |
| 9 | DFA US Vector Equity I | 0.03% | 2,093 | $10,172 | — | August 31, 2026 |
| 10 | Dimensional US Core Equity 2 ETF | 0.03% | 1,855 | $9,015 | — | September 30, 2026 |
| 11 | Strategic Advisers U.S. Total Stock | 0.03% | 1,600 | $7,776 | −1,100 (−40.7%) | August 31, 2026 |
| 12 | Avantis US Small Cap Equity ETF | 0.02% | 1,427 | $6,935 | — | September 30, 2026 |
| 13 | Dimensional Global Core Equity USD Acc | 0.02% | 1,152 | $5,599 | — | August 31, 2026 |
| 14 | Dimensional US Sustainability Core 1 ETF | 0.02% | 1,149 | $5,584 | — | September 30, 2026 |
| 15 | 1290 VT Micro Cap K | 0.02% | 1,090 | $5,297 | — | August 31, 2026 |
| 16 | Avantis U.S. Small Cap Equity G | 0.01% | 332 | $1,614 | — | June 30, 2026 |
| 17 | JHVIT Total Stock Market Index I | <0.01% | 224 | $1,089 | +46 (+25.8%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ALGS insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-10-25 | Carole Nuechterlein | Buy | $19.00 | 317,344 | $6.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ALGS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ALGS
Institutional investors own 42.2% of Aligos Therapeutics's shares and insiders 10.64%. The largest holder is Deep Track Capital, LP with 7.11% of the shares (444K), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 4 reduced their stake in the latest filings. Short interest is 13.36% of the float, or 14.01 days of average trading volume. The share count fell 51.0% since 2017.
Related: ALGS analyst forecast, ALGS key metrics. See the ALGS stock overview for the latest quote and news.
ALGS ownership FAQ
Who owns the most Aligos Therapeutics stock?
The largest shareholders of Aligos Therapeutics are Deep Track Capital, LP (7.11%), Alyeska Investment Group, L.P. (6.60%), Sio Capital Management, LLC (5.24%), Marshall Wace Asset Management Ltd (3.95%), Woodline Partners LP (2.84%).
What percentage of Aligos Therapeutics is owned by institutions?
Institutions hold 42.2% of Aligos Therapeutics's shares outstanding; insiders hold 10.64%.
Which funds own Aligos Therapeutics?
The largest fund holders of Aligos Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.06%), Fidelity Extended Market Index (0.43%), iShares Micro-Cap ETF (0.25%), DFA US Micro Cap I (0.13%), Fidelity Total Market Index (0.12%).
What is Aligos Therapeutics's short interest?
709K shares of Aligos Therapeutics were sold short, 13.36% of the float; at the average daily volume it would take 14.01 days to cover.
Are insiders buying or selling Aligos Therapeutics?
Of the latest 1 reported insider transactions in Aligos Therapeutics (since October 25, 2023), 1 were purchases and 0 were sales.
How many shares of Aligos Therapeutics are outstanding?
Aligos Therapeutics has 5.4M shares outstanding, of which 3.7M are in the public float.